Thyroid Cancer (Anaplastic Carcinoma)

    Actionable Target Abnormality Prevalence (%) Clinical Experience with Targeted Agent
    BRAF Mutation 26 Vemurafenib (BRAF inhibitor):
    • CR 1/7, PR 1/7, PD 4/7, NE 1/7 (12)
    Dabrafenib (BRAF inhibitor) ± trametinib (MEK inhibitor):
    • Case reports (13–16)Phase 1: cPR 69%. PFS and OS not reached, with 12-month estimates of, 79%, and 80%, respectively.
    PIK3CA Mutation 12 Everolimus (mTOR inhibitor):
    • SD with regression of tumor in 1/6 pts (6)
    PTEN Protein loss 11
    Miscellaneous N/A N/A Fosbretabulin (microtubule inhibitor and VE-cadherin/beta-catenin/AKT inhibitor):
    • Phase 2/3, with paclitaxel/carboplatin: OS 5 vs. 4 ith chemo alone (17)
    Other topics in Targets by Organ Site